

Sheet 1 of 1

FORM PTO-1449 PATENT & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01617K		APPLICATION NO.: 10/654,546		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Timothy J. Guzi et al.		FILING DATE: 09/03/2003		
				GROUP: 1624				
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
✓	AA	US 5,571,813	11/05/1996	Rühter et al.				
	AB	US 5,602,136	02/11/1997	Rühter et al.				
	AC	US 5,602,137	02/11/1997	Rühter et al.				
	AD	US 5,688,949	11/18/1997	Inoue et al.				
	AE	US 5,707,997	01/13/1998	Shoji et al.				
	AF	US 5,919,815	07/06/1999	Bradley et al.				
	AG	US 6,040,321	03/21/2000	Kim et al.				
	AH	US 6,191,131	02/20/2001	He et al.				
	AI	US 6,262,096	07/17/2001	Kim et al.				
	✓	AJ	US 6,413,974	07/02/2002	Dumont et al.			
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
✓	AK	EP 0 628 559	04/03/2002	Europe				
	✓	AL	EP 1 334 973	08/13/2003	Europe			
	✓	AM	WO 02/40485	05/23/2002	PCT			
	✓	AN	WO 02/50079	06/27/2002	PCT			
	✓	AO	WO 95/35298	12/28/1995	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
✓	AP	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-786.						
	✓	AQ	Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>Journal of Medical Chemistry</i> , Page EST:22.3, A-W.					
	✓	AR	Mettey et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects", <i>J. Med. Chem.</i> (2003), 46(2): 222-236.					
	✓	AS	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5- α]pyrimidines", <i>J. Med. Chem.</i> (1977), 20(2): 296-299.					
	✓	AT	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.					
	✓	AU	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243:527-536.					
	✓	AV	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.					
	✓	AW	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.					
✓	AX	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), 10: 620-626.						
EXAMINER 				DATE CONSIDERED 6/17/05				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01617K	APPLICATION NO.: 10/654,546
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Timothy J. Guzi et al.	
(Use several sheets if necessary)				FILING DATE: 09/03/2003	GROUP:

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
<i>g</i>	AA	6,107,305	08/22/2000	Misra et al.			
<i>g</i>	AB	6,413,974 B1	07/02/2002	Dumont et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
					YES	NO	
<i>g</i>	DE 102 23 917 A1	12/11/2003	Germany				
<i>g</i>	AL EP 0 628 559 A	12/14/1994	Europe				
<i>g</i>	AM WO 02/50079 A1	06/27/2002	WIPO				
<i>g</i>	AN WO 03/091256 A1	11/06/2003	WIPO				
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>g</i>	AQ Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)
	AR
	AS
	AT
	AU
	AV

EXAMINER <i>Jon McG</i>	DATE CONSIDERED <i>6/17/05</i>
----------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.